- Home
- AGIO vs BKD Comparison
AGIO vs BKD Comparison
Compare AGIO & BKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- BKD
- Stock Information
- Founded
- AGIO 2007
- BKD 2005
- Country
- AGIO United States
- BKD United States
- Employees
- AGIO N/A
- BKD N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- BKD Hospital/Nursing Management
- Sector
- AGIO Health Care
- BKD Health Care
- Exchange
- AGIO Nasdaq
- BKD Nasdaq
- Market Cap
- AGIO 1.4B
- BKD 1.6B
- IPO Year
- AGIO 2013
- BKD 2005
- Fundamental
- Price
- AGIO $35.00
- BKD $7.61
- Analyst Decision
- AGIO Buy
- BKD Buy
- Analyst Count
- AGIO 6
- BKD 5
- Target Price
- AGIO $57.40
- BKD $7.70
- AVG Volume (30 Days)
- AGIO 840.6K
- BKD 2.7M
- Earning Date
- AGIO 07-31-2025
- BKD 08-06-2025
- Dividend Yield
- AGIO N/A
- BKD N/A
- EPS Growth
- AGIO N/A
- BKD N/A
- EPS
- AGIO 11.13
- BKD N/A
- Revenue
- AGIO $40,875,000.00
- BKD $3,015,786,000.00
- Revenue This Year
- AGIO $18.94
- BKD $8.40
- Revenue Next Year
- AGIO $201.70
- BKD N/A
- P/E Ratio
- AGIO $3.15
- BKD N/A
- Revenue Growth
- AGIO 30.57
- BKD 4.14
- 52 Week Low
- AGIO $23.42
- BKD $4.45
- 52 Week High
- AGIO $62.58
- BKD $8.01
- Technical
- Relative Strength Index (RSI)
- AGIO 38.99
- BKD 55.96
- Support Level
- AGIO $37.09
- BKD $7.40
- Resistance Level
- AGIO $39.12
- BKD $7.90
- Average True Range (ATR)
- AGIO 1.78
- BKD 0.23
- MACD
- AGIO -0.67
- BKD -0.03
- Stochastic Oscillator
- AGIO 9.16
- BKD 34.17
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About BKD Brookdale Senior Living Inc.
Brookdale Senior Living Inc operates senior living communities throughout the United States. The company has three reportable segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRs). The majority of the revenue is generated from the Assisted Living and Memory Care segment, which offers housing and assistance with activities of daily living to its customers. The company generates revenue in the form of Resident Fees, which it receives in exchange for the services provided, and in the form of management fees from certain communities under contract in exchange for the management services provided.